Trial · NCT02845596
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
NCT02845596, Not applicable, Completed, Michael Pulsipher
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia. Trials, record NCT02845596. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02845596
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
- NCT number
- NCT02845596
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Michael Pulsipher
- Conditions
- Severe Aplastic Anemia
- Interventions
cyclosporine, Matched Unrelated Donor Hematopoietic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), methotrexate, fludarabine, cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
- First posted
- 2016-07-27
- Last updated
- 2025-05-11
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of patients randomized to HSCT that actually complete HSCT | 4 years | Feasibility of comparing outcomes of patients treated de novo with IST versus matched unrelated donor HSCT for pediatric acquired severe aplastic anemia as defined by percentage of patients randomized to HSCT that actually complete HSCT. |
| Secondary | Time from screening consent to randomization | 4 years | To measure the time from screening consent and randomization of patients to initiation of the preparative regimen of those randomized to HSCT. |
| Secondary | Number of patients that fail to receive their primary assigned therapy (HSCT or IST). | 4 years | Number of patients fail to receive their primary assigned therapy (HSCT or IST). |
| Secondary | Reasons why patients fail to receive their primary assigned therapy (HSCT or IST). | 4 years | Reasons why patients fail to receive their primary assigned therapy (HSCT or IST). |
| Secondary | Treatment-related mortality at one year from randomization in both arms | 1 Year | Number of deaths that are treatment related |
| Secondary | Overall Survival at one year from randomization in both arms | 1 Year | percentage of enrolled patients living at 1 year post randomization |
| Secondary | Time from randomization to neutrophil recovery in both arms | 4 years | Time from randomization to neutrophil recovery in both arms |
| Secondary | Time from randomization to platelet recovery in both arms | 4 years | Time from randomization to platelet recovery in both arms |
| Secondary | Time from randomization to red blood cell recovery in both arms | 4 years | Time from randomization to red blood cell recovery in both arms |
| Secondary | Time from randomization to cessation of immune suppression recovery in both arms | 4 years | Time from randomization to cessation of immune suppression recovery in both arms |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02845596
GET https://conductscience.org/api/trials/v1/NCT02845596/registered